ReviewChemSusChem2025
Enzymatic Degradation of PFAS: Current Status and Ongoing Challenges.
Review in ChemSusChem, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Vapor-Phase Detection of Perfluoroalkyl Acids using Amplifying Fluorescent Polymers.Small methods · 2026Article
- Enzymatic Defluorination of Perfluorooctanoic Acid by an Evolutionarily Distinct Haloacid Dehalogenase.Research square · 2026Article
- Heterogeneous PFAS Defluorination and Fluoride Upcycling into Medicinal Agents in Aqueous Electrolytes.ACS electrochemistry · 2026Article
- Machine Learning-Guided Synthetic Microbial Communities Enable Functional and Sustainable Degradation of Persistent Environmental Pollutants.Environmental science & technology · 2026Article
- Per- and polyfluoroalkyl substances (PFAS): persistence, toxicity, and emerging solutions.Bioprocess and biosystems engineering · 2026Review
- Reflections on bio-based PET and plastic waste management: a responsible research and innovation approach.Nature communications · 2026Review
- Current Research Advances and Future Prospects on Microbial Consortia for Sustainable PFAS Remediation.International journal of molecular sciences · 2026Review
- Microbial and molecular approaches for PFAS transformation in soils: prospects and limitations.RSC advances · 2026Review
- Per- and Polyfluoroalkyl Substances (PFAS): History, Current Concerns, and Future Outlook.Molecules (Basel, Switzerland) · 2025Review
- Enzymatic Degradation of PFAS: Current Status and Ongoing Challenges.ChemSusChem · 2025Review
- PFAS in water environments: recent progress and challenges in monitoring, toxicity, treatment technologies, and post-treatment toxicity.Environmental systems research · 2025Review
- Bridging single-species research and mixture reality: Emerging contaminants fate and transport in vadose zones.Journal of environmental qualityReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Per- and polyfluoroalkyl substances (PFAS) are often considered the quintessential example of industrial chemical pollution - they are toxic and ubiquitous environmental contaminants that are extremely difficult to degrade. There has been a large research focus on the development of effective and renewable degradation technologies. In comparison to traditional pollutant degradation techniques, such as advanced oxidation processes and electrochemistry, degradation of PFAS using extracellular enzymes offers an eco-friendly solution as enzymes are biodegradable, recyclable and have low energy and chemical requirements. This review outlines the current understanding of extracellular enzymatic degradation of PFAS with a focus on reported results and proposed degradation mechanisms. More importantly, this review highlights limitations that hinder the application of enzymes for PFAS degradation and proposes critical future research that is needed to improve the applicability of this promising remediation strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.